|Bid||4.2800 x 2900|
|Ask||4.2900 x 1400|
|Day's range||4.1700 - 4.3250|
|52-week range||4.0600 - 11.1000|
|Beta (5Y monthly)||1.76|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.
All that being said, biotech stocks in the middle of an important commercial launch or long-winded clinical trial can be powerful growth vehicles. Acadia Pharmaceuticals (NASDAQ: ACAD) and Clovis Oncology (NASDAQ: CLVS) have both lagged behind the broader markets in a big way in 2021, even though they were super-charged growth stocks in the not-so-distant past. While there's no guarantee that either of these names will regain its prior form as a top growth stock, these two biotech companies do sport the type of key assets to spark a comeback.
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.